Literature DB >> 21291689

Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B.

Allan Sniderman1, Andre Tremblay, Jean Bergeron, Claude Gagné, Patrick Couture.   

Abstract

OBJECTIVE: Our objective was to develop a simple algorithm that could be applied in routine clinical practice to diagnose type III hyperlipoproteinemia based on plasma total cholesterol, triglyceride and apolipoprotein (Apo) B.
METHODS: Analysis of plasma lipid, lipoprotein lipid, and apolipoprotein data from 1771 patients in a tertiary care lipid clinic, from whom all data had been collected prospectively by standardized methods. Of the 1771, based on the Fredrickson classification, 16 had type I hyperlipoproteinemia, 736 type IIa hyperlipoproteinemia, 371 type IIb hyperlipoproteinemia, 38 type III hyperlipoproteinemia, 509 type IV hyperlipoproteinemia, and 101 type V hyperlipoproteinemia.
RESULTS: Mean plasma ApoB was highest in type IIb (1.53 ± 0.36 g/L), borderline high (1.1 ± 0.23 g/L) in type IV, normal in type III and type V (1.04 ± 0.21 g/L and 0.96 ± 0.40 g/L, respectively) and low in type I (0.48 ± 0.16 g/L). In type III hyperlipoproteinemia, very low-density lipoprotein ApoB (ie, d<1.006 g/mL) accounted for 42.3% of total ApoB, a value that was substantially higher than in any of the other dyslipoproteinemias. The total cholesterol (TC)/ApoB ratio was similar in the uncommon dyslipoproteinemias-type I, III, and V hyperlipoproteinemia (10.5 ± 4.8, 8.7 ± 1.8, 10.3 ± 7.7, respectively)-and much higher than in the common dyslipoproteinemias-type IIa, IIb, and type IV hyperlipoproteinemia (5.0 ± 0.4, 4.6 ± 0.4, 4.9 ± 1.1, respectively). Notwithstanding that the TC/ApoB area under the curve-receiver operating characteristic (AUC-ROC) was very high (0.93), it did not discriminate among the uncommon dyslipoproteinemias. However, the triglyceride (TG)/ApoB ratio was much higher in type I (42.4 ± 28.8) and type V (25.6 ± 30.2) than in type III (5.8 ± 3.2). All cases of type III had a TC/ApoB ratio >6.2 and a TG/ApoB ratio of <10.0. Using these cutpoints, there were also no false positives. Based on the TC/ApoB ratio and the TG/ApoB ratio, the AUC-ROC was 0.99.
CONCLUSIONS: These data indicate that type III hyperlipoproteinemia can be reliably diagnosed based on plasma cholesterol, TG, and ApoB.

Entities:  

Year:  2007        PMID: 21291689     DOI: 10.1016/j.jacl.2007.07.006

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  12 in total

1.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

Review 2.  Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.

Authors:  Allan Sniderman; Patrick Couture; Jacqueline de Graaf
Journal:  Nat Rev Endocrinol       Date:  2010-04-27       Impact factor: 43.330

Review 3.  ApoB versus non-HDL-C: what to do when they disagree.

Authors:  Allan Sniderman; Ken Williams; Christa Cobbaert
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

4.  Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia).

Authors:  Vincent A Pallazola; Vasanth Sathiyakumar; Jihwan Park; Rachit M Vakil; Peter P Toth; Mariana Lazo-Elizondo; Emily Brown; Renato Quispe; Eliseo Guallar; Maciej Banach; Roger S Blumenthal; Steven R Jones; David Marais; Daniel Soffer; Allan D Sniderman; Seth S Martin
Journal:  Arch Med Sci       Date:  2019-08-02       Impact factor: 3.318

Review 5.  Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Authors:  Allan D Sniderman; Patrick Couture; Seth S Martin; Jacqueline DeGraaf; Patrick R Lawler; William C Cromwell; John T Wilkins; George Thanassoulis
Journal:  J Lipid Res       Date:  2018-05-16       Impact factor: 5.922

Review 6.  Hyperlipoproteinemia type 3: the forgotten phenotype.

Authors:  Paul N Hopkins; Eliot A Brinton; M Nazeem Nanjee
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

7.  Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles.

Authors:  Yuzhou Xue; Jian Shen; Weifeng Hong; Wei Zhou; Zhenxian Xiang; Yuansong Zhu; Chuiguo Huang; Suxin Luo
Journal:  Lipids Health Dis       Date:  2021-05-06       Impact factor: 3.876

8.  Unmasking of severe hypertriglyceridaemia associated with antipsychotic therapy by atypical eruptive xanthomas.

Authors:  Magdalena Kiedrowicz; Radosław M Kiedrowicz; Joanna Pietrzak-Halińska; Mariusz Pietrzak; Romuald Maleszka
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

9.  A new phenotypic classification system for dyslipidemias based on the standard lipid panel.

Authors:  Maureen Sampson; Rami A Ballout; Daniel Soffer; Anna Wolska; Sierra Wilson; Jeff Meeusen; Leslie J Donato; Erica Fatica; James D Otvos; Eliot A Brinton; Robert S Rosenson; Peter Wilson; Marcelo Amar; Robert Shamburek; Sotirios K Karathanasis; Alan T Remaley
Journal:  Lipids Health Dis       Date:  2021-11-27       Impact factor: 3.876

10.  Case Studies in Pediatric Lipid Disorders and Their Management.

Authors:  Ambika P Ashraf; Bhuvana Sunil; Vaneeta Bamba; Emily Breidbart; Preneet Cheema Brar; Stephanie Chung; Anshu Gupta; Aditi Khokhar; Seema Kumar; Marissa Lightbourne; Manmohan K Kamboj; Ryan S Miller; Nivedita Patni; Vandana Raman; Amy S Shah; Don P Wilson; Brenda Kohn
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.